Business
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass
About this update from Davita Inc.
[{"type":"image","alt":"Akebia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Akebia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_bsAI2TGvJhraBA7ZLgS7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849","width":300,"height":122}},"lazy":false},{"type":"text","content":"Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million","length":162,"tagName":"p"},{"type":"text","content":"DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics ","length":148,"tagName":"p"},{"type":"text","content":"Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC","length":97,"tagName":"p"},{"type":"text","content":"Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025","length":74,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2025 and recent business highlights.","length":305,"tagName":"p"},{"type":"text","content":"“Vafseo® (vadadustat) U.S. product launch momentum builds as we continued to add new prescribers, increase volume with existing writers, and importantly, progress efforts to further expand patient access to the therapy,” said John P. Butler, Chief Executive Officer of Akebia. “We are working to increase utilization at mid-sized dialysis organizations, and we expect by September, both Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC), the fourth and fifth largest dialysis organizations, will have operationalized protocols to simplify and expand Vafseo prescribing. Additionally, we are pleased that DaVita has begun ordering Vafseo to support an operational pilot in Q3, which we expect to lead to the opportunity for broad prescribing before year...